Nina (Das) Shah, MD, Oncology, San Francisco, CA, University of Texas M.D. Anderson Cancer Center

Nina(Das)ShahMD

Oncology San Francisco, CA

Hematologic Oncology

Physician

Dr. Shah is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Shah's full profile

Already have an account?

Education & Training

  • University of Texas Health Science Center - Houston
    University of Texas Health Science Center - HoustonFellowship, Hematology/Oncology, 2007 - 2010
  • New York Presbyterian Hospital
    New York Presbyterian HospitalResidency, Internal Medicine, 2002 - 2005
  • NYU School of Medicine
    NYU School of MedicineClass of 2002

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2016 - 2022
  • TX State Medical License
    TX State Medical License 2007 - 2017
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • Germline Variation Predicts Treatment Response in Multiple Myeloma
    Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and _Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology
    Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Cord Blood Regulatory T Cells Prevent Mutiple Myeloma Progression By Suppressing Inflammation
    Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in C... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Immunotherapy in Myeloma 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autolo... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • Dr. Shah Discusses Data on Ide-Cel and Melflufen, Both Granted Priority Review by FDA
    Dr. Shah Discusses Data on Ide-Cel and Melflufen, Both Granted Priority Review by FDAOctober 23rd, 2020
  • Expert Discusses CAR T-cell Therapy in Myeloma
    Expert Discusses CAR T-cell Therapy in MyelomaApril 23rd, 2020
  • Dr. Shah on Potential for Daratumumab Maintenance in Multiple Myeloma
    Dr. Shah on Potential for Daratumumab Maintenance in Multiple MyelomaFebruary 6th, 2020
  • Join now to see all

Hospital Affiliations